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Neuroendocrine tumours (NETs) are a family of neoplasms that come from neuroendocrine cells and express neural
markers, such as synaptophysin or chromogranin A.
The current classifications of these tumours are presented by the WHO 2000 classification, based on histological
parameters, and the WHO 2010 classification, based on the proliferative index, that divides the NETs into a
neuroendocrine tumour of a low grade, neuroendocrine tumour of a intermediate grade and neuroendocrine
carcinoma (NEC) of a high grade.
We are reporting a very rare case of a G1 low-grade neuroendocrine tumour (NET) of the ileum with a peritoneal
carcinomatosis.
This case is challenging because the tumour expresses low proliferative index as G1 tumours, but it has an
aggressive clinical behaviour such as node metastasis and peritoneal carcinomatosis.
The peritoneal carcinomatosis is not actually considered by the current classifications of NETs, so it is difficult to
predict the prognosis of this patient.
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This article represents the original observation of a low-
grade neuroendocrine tumour of the ileum debuting
with a bowel obstruction and peritoneal carcinomatosis.
Neuroendocrine tumours (NETs) are a family of neo-
plasms that arise from neuroendocrine cells and express
neural markers, such as synaptophysin or chromogranin
A. They are mainly distributed in the gastrointestinal tract.
Pancreatic neuroendocrine tumours are included in this
category (gastrointestinal-pancreatic neuroendocrine tu-
mours (GPNETs). The behaviour of NETs differs by ana-
tomic site [1], so it is important to define the tumour
localization for prognostic stratification.
Current classifications of NETs are the 2000 WHO
and the 2010 WHO classifications. The first is based
on histological parameters such as size, depth of inva-
sion, angiolymphatic invasion and metastases, and it* Correspondence: ministrini.silvia@me.com
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unless otherwise stated.divides the tumours into well-differentiated neuroen-
docrine tumour (WDNT), well-differentiated neuroen-
docrine carcinoma (WDNC) and poorly differentiated
neuroendocrine carcinoma (PDNC). The 2010 WHO
classification, instead, considers the proliferative activ-
ity of the tumours on the basis of their expression of
the Ki-67 index or the mitotic count [1-10], and it di-
vides the tumours into neuroendocrine tumour (NET)
of low grade, neuroendocrine tumour of intermediate
grade and neuroendocrine carcinoma (NEC - high grade).
So the two classifications consider different aspects of
these tumours and use different nomenclature.
Well/moderately differentiated NETs are relatively
low-aggressive tumours, with a rather indolent disease
course and good prognosis in most patients. The lymph
nodes and the liver are the prevalent metastatic sites.
Peritoneal carcinomatosis is a frequent complication of
high-grade aggressive tumours, but to our knowledge, it
has never been described in patients with low-grade
NETs.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 2000 TNM NETs classification
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NET of the ileum with peritoneal carcinomatosis at the
first diagnosis of the disease.
Case presentation
We describe the case of a 64-year-old man admitted to
our hospital for an intestinal obstruction caused by a
tumour of the ileum associated with pelvic peritoneal
carcinomatosis.
A preoperative CT scan showed an ileal solid mass of
4 cm in diameter with peritoneal fluid in Douglas and
radiologic signs of intestinal obstruction. No liver nor
thoracic focal lesions were found.
We performed an urgent surgical operation. At the
opening of the peritoneal cavity, we found a stenotic ileal
tumour, about 40 cm from the ileocecal valve, with a
mesenteric adenopathy of 4 cm and pelvic peritoneal
carcinomatosis. Ileal tract of 30 cm was resected and a
manual L-L anastomosis performed.
Pathologic evaluation of the resected specimen con-
firmed the diagnosis of a neuroendocrine tumour 2.7 ×
2 cm in size, with a metastatic node mass of 4 cm in diam-
eter. Only one node was positive for cancer localization.Figure 1 a, b Macroscopic aspects of ileal primitive tumour.The tumour presented serosa and perivisceral fat infiltra-
tions, perineural and lymphatic vessels invasion and mes-
enteric implants (Figure 1a, b). Our diagnosis was pT4N1
according to the 2010 American Joint Committee on
Cancer (AJCC) classification (Table 1).
An immunohistochemistry analysis revealed synapto-
physin and chromogranin A positivity and a Ki-67 ex-
pression <1%. Mitotic count/10 was 2 × 10 high-power
fields (HPF) and cells showed well differentiation. So,
according to the novel WHO 2010 classification for
GPNETs [1,4-6,11], we classified this tumour as G1-
NET.
The case was discussed in a multidisciplinary team,
consisting of oncologists, surgeons, radiation oncologists
and radiologists. To our knowledge, this is the first case
reported in literature of a low-grade NET with concomi-
tant peritoneal carcinomatosis. To exclude the presence
of another primitive tumour, we performed a positron
emission tomography with gallium-labeled somatostatine
analogues (DOTA-NOC PET) and a second look in aPrimary tumour (T)
T1 Tumour invades lamina propria or
submucosa and is size 1 cm or less
T2 Tumour invades muscolaris propria or
is size >1 cm
T3 Tumour invades through the muscolaris
propria into the subserosa or into the
nonperitonealized tissue
T4 Tumour invades the visceral peritoneum
(serosa) or any other organs or structures
Regional lymph nodes (N)
N0 No regional lymph nodes metastasis
N1 Regional lymph nodes metastasis
Distant metastasis (M)








IV AnyT anyN M1
Differentiation/grade Mitotic Count (10 HPF) Ki-67 index (%)
Well differentiated
Low-grade <2 > or = 2
Intermediate-grade 2 to 20 3 to 20
Poorly indifferentiated >20 >20
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complete systemic and peritoneal staging [12-14].
During the second surgical operation, multiple biopsies
of the metastatic nodules and parietal peritoneum were
done (left and right pelvic peritoneum, left and right dia-
phragmatic peritoneum) and a peritoneal cytology was
performed. The exploration revealed no other tumours.
According to the classification of peritoneal carcin-
omatosis, the laparoscopic staging showed a peritonial
cancer index (PCI) of 4 [12-14]. Peritoneal cytology was
negative for malignancy. At the histological examination,
carcinomatosis nodules showed the same features of the
primary tumour. So the final diagnosis was ileal G1
NET with peritoneal carcinomatosis T4N1M1, stage IV
(Figures 3a, b, 4a, b, and 5a, b).
The patient is currently under treatment with somatos-
tatine analogue and in follow-up with biannual DOTA-
NOC PET; at present, he is disease free.
Discussion
The gastropancreatic neuroendocrine neoplasms (GEP-NEN)
are a heterogeneous group of tumours characterized byFigure 2 a, b Laparoscopic second look.
Figure 3 Microscopic and molecular aspects of the ileal tumour (a)
and the carcinomatosis nodules (b).the expression of the neural antigens such as chromogra-
nin A or synaptophysin.
They are relatively rare but with an increasing inci-
dence rate in the last years [2].
The term carcinoid was proposed for the first time in
1907 by S. Oberndorfer, and it is nowadays traditionally
used although it is not mentioned in the current classifi-
cation of the neuroendocrine neoplasms (NEN).
In 2000, the WHO revised the previous classification
system of 1980. Neuroendocrine tumours were divided
into three groups, considering various histological pa-
rameters, such as size, depth of invasion, angiolymphatic
invasion and metastases: WDNT or carcinoid; WDNC
or malignant carcinoid; PDNC [1,3].
In 2010, a revised version of the previous WHO classi-
fication appeared (Table 2), not based on histological pa-
rameters, but on proliferation rate, expression of Ki-67
index, or on mitotic count, calculated by the number of
mitosis/10 HPF [4-6].
The category of well-differentiated neuroendocrine
carcinoma of WHO 2000 does not exist anymore in this
Figure 4 Microscopic and molecular aspects of the ileal tumour (a)
and the carcinomatosis nodules (b).
Figure 5 Microscopic and molecular aspects of the ileal tumour (a)
and the carcinomatosis nodules (b).
Table 2 2010 WHO NETs classification
Definition Grade Ki-67% Mitotic index
NET - neuroendocrine tumour,
low grade
G1 ≤2 <2
NET - neuroendocrine tumour,
intermediate grade
G2 3 to 20 2 to 20
NET - neuroendocrine carcinoma,
high grade
G3 >20 >20
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nant with the potential to metastasize [1].
In a recent study of Yamaguchi T. et al. [7], consid-
ering a group of 45 patients with diagnosis of G1 and
G2-NET, metastases were observed also in the G1-NET.
In the metastatic group of seven patients, four showed a
Ki-67 ≤ 2. Metastasis was observed in the liver, lungs
and lymph nodes, and one patient presented a local
recurrence.
Clinical behaviour of the NEN is very heterogeneous:
NEC are considered extremely aggressive, with a bad
prognosis, instead of NET-G1, that are relatively indo-
lent [6,15].
Miller HC et al. analyzed the metastatic rate in a co-
hort of 161 patients with NEN and found out that me-
tastasized tumours were noted in 46.1% of the G1 cases,
77.8% of the G2 cases and 100% of the G3 cases. In spite
of this, relatively high incidence of metastasis also in G1
tumour; 87% of G1 cases are alive after 3 years [16].
So it is mandatory in the pathology report to specify
the grade or differentiation of the tumour. Indeed, the
terms neuroendocrine carcinoma and neuroendocrinetumour, without reference to these parameters, are con-
sidered inadequate for prognosis or therapy [6,8].
The proliferative rate can be assessed as the number
of mitosis per unit area of tumour or as the percentage
of proliferation marker Ki-67.
Despite the new classification of NET, WHO 2010, many
works are based on the old WHO 2000 classification, mak-
ing an analytic comparison of the data very difficult.
Some studies that compared the histological features
of the WHO 2000 classification to proliferative index of
the WHO 2010 classification in predicting metastasis
have shown that the Ki-67 index is the best parameter
[4,7]. Metastasis is more frequent in the liver, lymph
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solitary atrial myocardial metastasis is reported [17].
Liver metastasis were found between 20% and 60% of
the NETs [18,19].
In literature, some cases of small bowel NETs-
peritoneal carcinomatosis are reported [12,13,19-22], but
at our knowledge, a case of well-differentiated neuroen-
docrine tumour of ileum with single node metastasis
and peritoneal carcinomatosis has never been described.
Metastatic G1 well-differentiated NETs are described
in literature [7,15,20,21,23,24], and the liver is the most
frequent site of neoplastic spreading, but there are no
reports about peritoneal carcinomatosis in G1 NET.
G1 NETs are considered relatively indolent [6]. Stros-
berg J et al. reported a survival rate at 2 and 5 years of
100% and 85%, respectively, for G1 NETs, and consider-
ing the time between diagnosis of metastasis and death
from any cause, median survival was not reached in the
well-differentiated NETs [20].
In spite of this benign behaviour of G1 NETs, we re-
port a case of potentially aggressive well-differentiated
G1 NET. Although the low proliferative index and mi-
totic rate (Ki-67 < 1% and mitotic count 2x10 HPF), the
tumour showed lymphatic metastasis, serosa and peri-
visceral fat infiltrations, perineural and lymphatic vessels
invasion, mesenteric implants and above all peritoneal
carcinomatosis.
We decided to perform a second surgical operation for
PCI staging in a laparoscopic way because some studies
demonstrated that laparoscopy is a safe and accurate tech-
nique for peritoneal carcinomatosis staging [14,25].
We started with adhesiolysis procedure, and after, the
peritoneal cavity was totally explored for the allocation
of PCI using the Sugarbaker scoring system (Figure 6).Figure 6 PCI scoring system.Such as for ovarian cancer, we accomplished a periton-
eal washing for cytology examination and multiple ran-
dom peritoneal biopsies of normal surfaces and neoplastic
implants [25]. We think that, during surgery, a complete
peritoneal cavity exploration should be always performed
for these tumours to avoid a wrong staging of the disease,
and laparoscopy could be, in selected cases, a useful
technique.
Peritoneal nodes of carcinomatosis presented the same
features of the primary tumour, and also Ki-67 and mitotic
count were the same. According to AJCC 2010, tumour
was classified as pT4N1, stage IV [8,10,11,26-29].
In some cases metastasis have a more aggressive be-
haviour in relation to primary tumours. A recent study
compared the expression of the Ki-67 index between
primary tumours and liver metastasis in 30 patients with
NETs [23]. Actually, in one third of the patients with
well-differentiated NETs, liver metastasis had an elevated
Ki-67 index. Four cases were small bowel NETs and
three of these were upgraded from G1 to G2 (two cases)
or from G2 to G3 (one case).
In our, case both the ileal tumour and the carcinoma-
tosis nodules showed the same Ki-67 index and a well
differentiation grade. This means that the tumour has
an unusual behaviour because it shows immunohisto-
chemical markers of low malignancy, such as other
indolent G1 NET, but histological features of high
aggressiveness.
The work of Pape UF et al. [28], comparing the prog-
nostic relevance of the TNM classification system to the
grading system, reports a 5-year survival rate of 55.4%
for stage IV NETs, according to the TNM classification
system and of 95.7% for G1 NETs, according to the
grading system.
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458 patients with stage IV midgut NETs is reported around
70% against 100% of stage I, and the 5-year probability of
survival of 499 patients with low-grade midgut NETs is
near 100% [29].
The prognosis of the well-differentiated NET with peri-
toneal carcinomatosis could not be established since neither
the WHO 2010 classification nor the TNM classification
system could be useful for prognostic stratification.
Conclusions
GPNETs are rare tumours, and large case series are diffi-
cult to collect and analyze, although their incidence is
increasing. For these reasons, it is crucial for scientists
to employ a universally accepted diagnostic system with
a common language.
Both histological parameters (such as tumour dimen-
sions, lymphatic and vascular invasion, nodes involvement,
metastasis, etc.) and proliferative index (such as Ki-67 or
mitotic count) are important in prognostic stratification.
Our case is challenging because the tumour expresses
low proliferative index such as G1 tumours, but it has
an aggressive clinical behaviour such as node metastasis
and peritoneal carcinomatosis.
The peritoneal carcinomatosis is actually not consid-
ered by the current classifications of NETs, so it is diffi-
cult to predict the prognosis of this patient.
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